Preferred Label : Talquetamab;
NCIt synonyms : GPRC5D x CD3 Bispecific Antibody JNJ-64407564; Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564; GPRC5D/CD3 DuoBody Antibody JNJ-64407564; GPRC5D x CD3 DuoBody Antibody JNJ-64407564; Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564; Talquetamab-tgvs;
NCIt definition : A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen,
and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated
antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab
binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results
in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte
(CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain
tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells,
and plays a key role in tumor cell proliferation.;
UNII : 4W3KFI3TN3;
CAS number : 2226212-40-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2226212-40-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : JNJ 64407564; JNJ-64407564;
NCI Metathesaurus CUI : CL545429;
Codes from synonyms : 111584;
Origin ID : C171840;
UMLS CUI : C5419330;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
https://www.ema.europa.eu/en/medicines/human/EPAR/talvey
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Talquetamab
Talquetamab
talquetamab
orphan drug production
multiple myeloma
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
injections, subcutaneous
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
